Three Trials. Three Continents. One Result.
The first major trial of R-Alpha Lipoic Acid for diabetic nerve concerns.
328 patients across multiple research centers received either 600mg of R-ALA or a placebo.
The result:"82.5% of patients in the 600mg group reported meaningful symptom improvement, compared to 57.6% on placebo.
"Total Symptom Scores dropped by 63.5% in the R-ALA group. Published in Diabetologia, Ziegler et al.
The trial that proved oral R-ALA works — not just IV delivery.
181 diabetic patients took 600mg of R-ALA daily for 5 weeks.
Researchers reported"significant improvements in neuropathic symptoms and deficits" with the 600mg oral dose, establishing it as the optimal balance of efficacy and tolerability. Published in Diabetes Care, Ziegler et al.
The longest and largest trial of R-ALA ever conducted.
460 patients across 36 research centers in the US, Canada, and Europe took 600mg of R-ALA daily for 4 full years.
Researchers concluded R-ALA produced"clinically meaningful improvement and prevention of progression of neuropathic impairments" over the duration of the study. Published inDiabetes Care, Ziegler et al.
Across All Three Trials, R-ALA Was Shown to:
-
Improve Symptoms in as Little as 5 Weeks
-
Deliver an 82.5% Response Rate
-
Reduce Total Symptom Scores by 63.5%
-
Halt Progression Over 4 Years of Use



